This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Moleculin Biotech (MBRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy
by Zacks Equity Research
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Lantheus (LNTH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Lantheus' (LNTH) fourth-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
by Zacks Equity Research
Moleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.
Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up
by Zacks Equity Research
Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarcoma lung metastases. The stock rises 10%.
Here's Why Moleculin Biotech, Inc. (MBRX) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Moleculin Biotech, Inc. (MBRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Moleculin Biotech, Inc. (MBRX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Moleculin Biotech, Inc. (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Moleculin Surges on Manufacturing Deal for Coronavirus Therapy
by Zacks Equity Research
Moleculin (MBRX) signs an agreement with Sterling Pharma Solutions for manufacturing and supply of WP1122, which is being developed as potential treatment for COVID-19.
Is Moleculin Biotech (MBRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (MBRX) Outperforming Other Medical Stocks This Year?
Moleculin Biotech, Inc. (MBRX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Moleculin Biotech, Inc. (MBRX) closed at $0.96, marking a -0.38% move from the previous day.
Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MBRX) Outperforming Other Medical Stocks This Year?
Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MBRX) Outperforming Other Medical Stocks This Year?
Seattle Genetics' Adcetris Label Expands in EU for Lymphoma
by Zacks Equity Research
Seattle Genetics (SGEN) secures a nod from the European Commission for Adcetris to treat adult patients with previously untreated systemic anaplastic large cell lymphoma.
Agenus' (AGEN) IND for iNKT Therapy Gets FDA Acceptance
by Zacks Equity Research
The FDA clears Agenus' (AGEN) IND application for allogeneic iNKT therapy, agenT-797, which is being developed to treat cancer as well as the deadly COVID-19 pandemic.
Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MBRX) Outperforming Other Medical Stocks This Year?
AMAG Pharmaceuticals (AMAG) Reports Q1 Loss, Beats on Revenues
by Zacks Equity Research
AMAG Pharmaceuticals' (AMAG) loss narrows year over year while sales top estimates in the first quarter of 2020. The company scraps 2020 outlook due to the plaguing pandemic effect.
Moleculin Biotech, Inc. (MBRX) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Moleculin Biotech, Inc. (MBRX) closed the most recent trading day at $1.07, making no change from the previous trading session.
Moleculin Biotech, Inc. (MBRX) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Moleculin Biotech, Inc. (MBRX) closed the most recent trading day at $1.14, making no change from the previous trading session.
Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MBRX) Outperforming Other Medical Stocks This Year?
Moleculin (MBRX) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
Moleculin (MBRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Is Moleculin Biotech (MBRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (MBRX) Outperforming Other Medical Stocks This Year?
Moleculin Completes Enrollment in Early-Stage Cancer Study
by Zacks Equity Research
Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.
Moleculin Files New Patents for Cancer Candidate Annamycin
by Zacks Equity Research
Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.
Amarin Down on Lower '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.